Roth Capital Starts Bionano Genomics (BNGO) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
UPDATE: Maxim Group Starts Bionano Genomics (BNGO) at Buy
September 25, 2018 7:41 AM EDT(Updated - September 25, 2018 7:57 AM EDT)
(updated to add analyst comments)
Maxim Group analyst Jason McCarthy initiates coverage on Bionano Genomics (NASDAQ: BNGO) with a Buy rating and a price target of $11.00.
McCarthy highlighted:
We are initiating coverage of Bionano Genomics with a Buy rating and $11 price target. Bionanos Saphyr could be the bridge between next-gen sequencing... More